ClinicalTrials.gg
CompletedNCT02008682Updated Mar 9, 2017Results posted

The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes

A Phase 4 interventional study of liraglutide and sitagliptin in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 25 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-09.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
368
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
31st of 151
368 · median 62
Started
2013
with 17 others
Phase 4
48 of 151
1 open now
Registered
88th of 151
by date
Lead sponsor
63 of 151
Novo Nordisk A/S

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 31st largest by enrollment, is one of 18 that started in 2013, is one of 48 in phase 4, and was the 88th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of liraglutide compared to sitagliptin, both as add-on to metformin in Chinese subjects with type 2 diabetes inadequately controlled on metformin monotherapy. Eligible subjects will continue their metformin background treatment during the trial.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 368 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age at least 18 years and below 80 years at the time of signing
  • Subjects diagnosed type 2 diabetes mellitus and treated with metformin monotherapy at a stable dose of at least 1500 mg daily or maximum tolerated dose above or equal to 1000 mg daily for at least 60 days prior to screening
  • 7.0-10.0% (both inclusive)
  • below or equal to 45.0 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Treatment with glucose lowering agent(s) other than stated in the inclusion criteria in a period of 60 days prior to screening. An exception is short-term treatment (below or equal to 7 days in total) with insulin in connection with intercurrent illness
  • History of chronic pancreatitis or idiopathic acute pancreatitis
  • Any chronic disorder or severe disease which at the discretion of the investigator might jeopardise subject's safety or compliance with the protocol
  • Screening calcitonin value above or equal to 50 ng/l
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
  • Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)
  • Any to liraglutide, sitagliptin or metformin according to local labelling
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
368 participants (actual)

Study arms

  • Experimental
    Liraglutide 1.8 mg + metformin

    2-week screening period, 26-week treatment duration, and a 1-week follow-up period

    Drug: liraglutide

  • Active comparator
    Sitagliptin 100 mg + metformin

    2-week screening period, 26-week treatment duration, and a 1-week follow-up period

    Drug: sitagliptin

Interventions

  • Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.

  • Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Haemoglobin (HbA1c)

    Mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 26.

    Time frame: Week 0, week 26

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose

    Mean change from baseline in fasting plasma glucose (FPG) at Week 26.

    Time frame: Week 0, week 26

  2. Change From Baseline in 7-point Self-measured Plasma Glucose Profile

    Mean change from baseline in mean of 7-point self-measured plasma glucose at week 26. The 7-point self-measured plasma glucose levels were measured before and after (120 minutes after the start of the meal) the three main meals (breakfast, lunch and dinner), and at bed time.

    Time frame: Week 0, week 26

  3. Subjects Who Achieve (Yes/no) HbA1c Below 7.0 % (American Diabetes Association Target)

    Calculated as the percentage of subjects achieving treatment target of HbA1c \< 7.0% at Week 26

    Time frame: After 26 weeks of treatment

  4. Subjects Who Achieve (Yes/no) HbA1c Below or Equal to 6.5 % (American Association of Clinical Endocrinologists Target)

    Calculated as the percentage of subjects achieving treatment target of HbA1c \<= 6.5% at Week 26

    Time frame: After 26 weeks of treatment

  5. Number of Confirmed Hypoglycaemic Episodes

    confirmed hypoglycaemic episode defined as severe (unable to treat her/himself) or biochemically confirmed by a plasma glucose \< 3.1 mmol/L

    Time frame: Weeks 0-26

08

Results

Posted Dec 22, 2015

Participant flow

This trial was conducted at 25 sites in China.

Participant flow — Overall Study
MilestoneLiraglutideSitagliptin
Started184184
Exposed183184
Completed157170
Not completed2714

Outcome measures

PrimaryChange From Baseline in Glycosylated Haemoglobin (HbA1c)

Mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 26.

Time frame:
Week 0, week 26
Reported as:
Mean · Percent (%) glycosylated haemoglobin
Change From Baseline in Glycosylated Haemoglobin (HbA1c)
Percent (%) glycosylated haemoglobinLiraglutideSitagliptin
Change From Baseline in Glycosylated Haemoglobin (HbA1c)-1.666 ± 0.9982-0.969 ± 0.9742
SecondaryChange From Baseline in Fasting Plasma Glucose

Mean change from baseline in fasting plasma glucose (FPG) at Week 26.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Plasma Glucose
mmol/LLiraglutideSitagliptin
Change From Baseline in Fasting Plasma Glucose-2.347 ± 2.1655-1.205 ± 2.2961
SecondaryChange From Baseline in 7-point Self-measured Plasma Glucose Profile

Mean change from baseline in mean of 7-point self-measured plasma glucose at week 26. The 7-point self-measured plasma glucose levels were measured before and after (120 minutes after the start of the meal) the three main meals (breakfast, lunch and dinner), and at bed time.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in 7-point Self-measured Plasma Glucose Profile
mmol/LLiraglutideSitagliptin
Change From Baseline in 7-point Self-measured Plasma Glucose Profile-2.25 ± 2.244-1.36 ± 2.204
SecondarySubjects Who Achieve (Yes/no) HbA1c Below 7.0 % (American Diabetes Association Target)

Calculated as the percentage of subjects achieving treatment target of HbA1c \< 7.0% at Week 26

Time frame:
After 26 weeks of treatment
Reported as:
Number · percentage of subjects
Subjects Who Achieve (Yes/no) HbA1c Below 7.0 % (American Diabetes Association Target)
percentage of subjectsLiraglutideSitagliptin
Subjects Who Achieve (Yes/no) HbA1c Below 7.0 % (American Diabetes Association Target)76.552.6
SecondarySubjects Who Achieve (Yes/no) HbA1c Below or Equal to 6.5 % (American Association of Clinical Endocrinologists Target)

Calculated as the percentage of subjects achieving treatment target of HbA1c \<= 6.5% at Week 26

Time frame:
After 26 weeks of treatment
Reported as:
Number · percentage of subjects
Subjects Who Achieve (Yes/no) HbA1c Below or Equal to 6.5 % (American Association of Clinical Endocrinologists Target)
percentage of subjectsLiraglutideSitagliptin
Subjects Who Achieve (Yes/no) HbA1c Below or Equal to 6.5 % (American Association of Clinical Endocrinologists Target)61.726.3
SecondaryNumber of Confirmed Hypoglycaemic Episodes

confirmed hypoglycaemic episode defined as severe (unable to treat her/himself) or biochemically confirmed by a plasma glucose \< 3.1 mmol/L

Time frame:
Weeks 0-26
Reported as:
Number · episodes
Number of Confirmed Hypoglycaemic Episodes
episodesLiraglutideSitagliptin
Number of Confirmed Hypoglycaemic Episodes21

Adverse events

Collected over Weeks 0-26. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide—3/183 (1.6%)65/183 (35.5%)
Sitagliptin—6/184 (3.3%)14/184 (7.6%)
Most frequent serious events
Most frequent serious events
EventLiraglutideSitagliptin
Sudden hearing lossEar and labyrinth disorders1/1830/184
BronchitisInfections and infestations1/1830/184
Diabetic ketoacidosisMetabolism and nutrition disorders1/1830/184
Gastric ulcerGastrointestinal disorders0/1831/184
HaemorrhoidsGastrointestinal disorders0/1831/184
Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1831/184
Thymoma malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1831/184
Atrial fibrillationCardiac disorders0/1831/184
Cerebral infarctionNervous system disorders0/1831/184
Most frequent other events
Most frequent other events
EventLiraglutideSitagliptin
NauseaGastrointestinal disorders27/1831/184
Decreased appetiteMetabolism and nutrition disorders20/1831/184
DiarrhoeaGastrointestinal disorders15/1834/184
Lipase increasedInvestigations11/1838/184

Baseline characteristics

Safety analysis set included all subjects receiving at least one dose of investigational product.

Age, Continuous
Age, Continuous(years)LiraglutideSitagliptinTotal
Mean51.7 ± 10.751.4 ± 11.051.5 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)LiraglutideSitagliptinTotal
Female8167148
Male102117219
Body mass index (BMI)
Body mass index (BMI)(kg/m^2)LiraglutideSitagliptinTotal
Mean27.32 ± 3.38927.16 ± 4.02927.24 ± 3.720
Body weight
Body weight(kg)LiraglutideSitagliptinTotal
Mean76.17 ± 13.56275.78 ± 15.08975.98 ± 14.330
Duration of diabetes
Duration of diabetes(years)LiraglutideSitagliptinTotal
Mean5.31 ± 4.395.22 ± 5.405.27 ± 4.92
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)LiraglutideSitagliptinTotal
Mean9.26 ± 2.2169.46 ± 2.2379.36 ± 2.226
Glycosylated haemoglobin A1c (HbA1c)
Glycosylated haemoglobin A1c (HbA1c)(Percent (%) glycosylated haemoglobin)LiraglutideSitagliptinTotal
Mean8.14 ± 0.8338.11 ± 0.7808.12 ± 0.806
09

Study locations

25 sites
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100071, China
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100700, China
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100853, China
  • Novo Nordisk Investigational Site
    ChongQing, Chongqing 404000, China
  • Novo Nordisk Investigational Site
    Cangzhou, Hebei 061000, China
  • Novo Nordisk Investigational Site
    Hengshui, Hebei 053000, China
  • Novo Nordisk Investigational Site
    Shijiazhuang, Hebei 050000, China
  • Novo Nordisk Investigational Site
    Shijiazhuang, Hebei 050051, China
  • Novo Nordisk Investigational Site
    Nanjing, Jiangsu 210011, China
  • Novo Nordisk Investigational Site
    Nanjing, Jiangsu 210012, China
  • Novo Nordisk Investigational Site
    Nanjing, Jiangsu 210029, China
  • Novo Nordisk Investigational Site
    Suzhou, Jiangsu 215004, China
  • Novo Nordisk Investigational Site
    Wuxi, Jiangsu 214023, China
  • Novo Nordisk Investigational Site
    Zhenjiang, Jiangsu 212001, China
  • Novo Nordisk Investigational Site
    Nanchang, Jiangxi 330006, China
  • Novo Nordisk Investigational Site
    Changchun, Jilin 130041, China
  • Novo Nordisk Investigational Site
    Dalian, Liaoning 116033, China
  • Novo Nordisk Investigational Site
    Shenyang, Liaoning 110021, China
  • Novo Nordisk Investigational Site
    Qingdao, Shandong 266003, China
  • Novo Nordisk Investigational Site
    Shanghai, Shanghai 200080, China
  • Novo Nordisk Investigational Site
    Shanghai, Shanghai 200092, China
  • Novo Nordisk Investigational Site
    Shanghai, Shanghai 200120, China
  • Novo Nordisk Investigational Site
    Shanghai, Shanghai 200240, China
  • Novo Nordisk Investigational Site
    Shanghai, Shanghai 201199, China
  • Novo Nordisk Investigational Site
    Beijing, 101200, China
10

References and documents

Publications

  • Zang L, Liu Y, Geng J, Luo Y, Bian F, Lv X, Yang J, Liu J, Peng Y, Li Y, Sun Y, Bosch-Traberg H, Mu Y. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial. Diabetes Obes Metab. 2016 Aug;18(8):803-11. doi: 10.1111/dom.12674. Epub 2016 May 20. PubMed 27060930 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2013
First posted
Dec 11, 2013
Start
Dec 2013
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Dec 22, 2015
Last update
Mar 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02008682
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 11, 2013
Start date
Dec 2013
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Dec 22, 2015
Last update
Mar 9, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion